A PROSPECTIVE, RANDOMIZED COMPARATIVE TRIAL OF MIZORIBINE VERSUS MYCOPHENOLATE MOFETIL IN COMBINATION THERAPY WITH TACROLIMUS AND BASILIXIMAB FOR LIVING DONOR RENAL TRANSPLANTATION

INTERVENTION: Tacrolimus + basiliximab + steroid + mizoribine Tacrolimus + basiliximab + steroid + cellcept CONDITION: Kidney transplantation PRIMARY OUTCOME: Rejection (incidence, types, severity) SECONDARY OUTCOME: Patient survival, graft survival, incidence of adverse effects / abnormalities in the laboratory values. INCLUSION CRITERIA: 1.Living donor kidney transplantation. 2.Primary kidney transplantation. 3.ABO blood type compatible (including semi‐compatible). 4.Gender free, any case of uremia. The patient or whose family has submitted (if the patient is showing disturbance of consciousness or decreased ability to understand) written consent forms based on their free choice once adequate information and understandings are obtained regarding the study upon the participation.